179 related articles for article (PubMed ID: 36958951)
41. Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
Brabender D; Ballard A; Kim S; Hovanessian-Larsen L; Sener SF
Breast Cancer Res Treat; 2024 Aug; 206(3):595-602. PubMed ID: 38700572
[TBL] [Abstract][Full Text] [Related]
42. Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study.
García-Novoa A; Acea-Nebril B; Díaz Carballada C; Bouzón Alejandro A; Conde C; Cereijo Garea C; Varela JR; Santiago Freijanes P; Antolín Novoa S; Calvo Martínez L; Díaz I; Rodríguez Martínez S; Mosquera Oses J
Ann Surg Oncol; 2021 Feb; 28(2):958-967. PubMed ID: 32725521
[TBL] [Abstract][Full Text] [Related]
43. Early reflector localization improves the accuracy of localization and excision of a previously positive axillary lymph node following neoadjuvant chemotherapy in patients with breast cancer.
Balija TM; Braz D; Hyman S; Montgomery LL
Breast Cancer Res Treat; 2021 Aug; 189(1):121-130. PubMed ID: 34159474
[TBL] [Abstract][Full Text] [Related]
44. Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes?
Costarelli L; Arienzo F; Broglia L; La Pinta M; Scavina P; Meli EZ; Colavito MH; Ascarelli A; Campagna D; Mastropietro T; Manna E; Amato M; Andrulli AD; Schiavone A; Minelli M; Fortunato L
Ann Surg Oncol; 2024 May; 31(5):3186-3193. PubMed ID: 38427160
[TBL] [Abstract][Full Text] [Related]
45. Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement.
de Wild SR; Koppert LB; van Nijnatten TJA; Kooreman LFS; Vrancken Peeters MTFD; Smidt ML; Simons JM
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38531689
[TBL] [Abstract][Full Text] [Related]
46. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
[TBL] [Abstract][Full Text] [Related]
47. Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy: Skin Mark clipped Axillary nodes Removal Technique (SMART trial).
Lim GH; Teo SY; Gudi M; Ng RP; Pang J; Tan YS; Lee YS; Allen JC; Leong LCH
Cancer Med; 2020 Mar; 9(6):1978-1985. PubMed ID: 31970894
[TBL] [Abstract][Full Text] [Related]
48. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
[TBL] [Abstract][Full Text] [Related]
49. Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients.
Acea-Nebril B; García-Novoa A; Bouzón Alejandro A; Díaz Carballada C; Conde Iglesias C
Breast; 2023 Dec; 72():103592. PubMed ID: 37857128
[TBL] [Abstract][Full Text] [Related]
50. The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer.
Cavalcante FP; Zerwes FP; Souza ABA; Ziegelmann PK; Alcantara R; Cardoso A; Mattar A; Millen EC; Frasson AL
Eur J Surg Oncol; 2024 Mar; 50(3):107967. PubMed ID: 38262300
[TBL] [Abstract][Full Text] [Related]
51. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
[TBL] [Abstract][Full Text] [Related]
52. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients.
Simons JM; Scoggins ME; Kuerer HM; Krishnamurthy S; Yang WT; Sahin AA; Shen Y; Lin H; Bedrosian I; Mittendorf EA; Thompson A; Lane DL; Hunt KK; Caudle AS
Ann Surg Oncol; 2021 Aug; 28(8):4277-4283. PubMed ID: 33417121
[TBL] [Abstract][Full Text] [Related]
53. Targeted axillary dissection after neoadjuvant systemic therapy in patients with node-positive breast cancer.
Kanesalingam K; Sriram N; Heilat G; Ng EE; Meybodi F; Elder E; Brennan M; French J
ANZ J Surg; 2020 Mar; 90(3):332-338. PubMed ID: 31845501
[TBL] [Abstract][Full Text] [Related]
54. Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy.
Cao XS; Li HJ; Cong BB; Sun X; Qiu PF; Liu YB; Wang CJ; Wang YS
Oncotarget; 2016 Nov; 7(45):74074-74081. PubMed ID: 27738336
[TBL] [Abstract][Full Text] [Related]
55. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
[TBL] [Abstract][Full Text] [Related]
56. New horizons in imaging and surgical assessment of breast cancer lymph node metastasis.
Arjmandi F; Mootz A; Farr D; Reddy S; Dogan B
Breast Cancer Res Treat; 2021 Jun; 187(2):311-322. PubMed ID: 33982209
[TBL] [Abstract][Full Text] [Related]
57. Targeted axillary dissection after neoadjuvant chemotherapy for highly selective patients with initial cN1 breast cancer: A single-center prospective trial.
Chen X; Lu Z; Wang C; Lyu M; Qiao J; Sun X; Li L; Zhang C; Liu Z
Chin Med J (Engl); 2024 Jun; 137(12):1421-1430. PubMed ID: 38557731
[TBL] [Abstract][Full Text] [Related]
58. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
[TBL] [Abstract][Full Text] [Related]
59. Lymphoscintigraphy and gamma probe tracing in detecting breast cancer lymph node involvement: can they replace axillary lymph node dissection?
Vaggelli L; Castagnoli A; Distante V; Orzalesi L; Cataliotti L; Cesco P
Tumori; 2000; 86(4):322-4. PubMed ID: 11016716
[TBL] [Abstract][Full Text] [Related]
60. Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers.
Yang J; He T; Wu Y; Fu Z; Lv Q; Lu S; Wang X; Li H; Wang J; Chen J
Breast Cancer Res Treat; 2022 Apr; 192(3):573-582. PubMed ID: 35129717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
